Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous administration, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
Is Novo Nordisk Stock a Buy?
It hasn't been a great period for investors in Novo Nordisk (NVO -5.27%) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs. Its shares are down by more than 20% in the last 12 months, and, given a few new competitive developments, the next 12 months might not see much in the way of relief for shareholders unless there's an upset of some kind.
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's what Wall Street analysts say about the inclusion:
Novo Nordisk shares fall after Ozempic, Wegovy selected for Medicare price negotiations
Novo Nordisk (NYSE:NVO) shares plummeted after the US Medicare program announced it plans to include the firm's weight loss medications in its second round of price negotiations. Shares of the Danish drugmaker fell 4.4% to about $79 on Friday morning, bringing the stock's losses to 25.5% in the last 12 months.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Analysts at Argus Research say the stock is now trading at 22 times its estimated 2025 earnings.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday.
Novo Nordisk says high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday that a late-stage trial with 7.2 milligram (mg) of semaglutide, a high-dose version of the active ingredient used in its blockbuster obesity drug Wegovy, helped overweight patients cut their weight by 20.7%.
Finally An Attractive Entry Point Into Novo Nordisk
Finally An Attractive Entry Point Into Novo Nordisk
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
